Novartis AG ADR (NVS)vsVuzix Corp Cmn Stk (VUZI)
NVS
Novartis AG ADR
$148.18
-1.02%
HEALTHCARE · Cap: $286.44B
VUZI
Vuzix Corp Cmn Stk
$2.17
-3.56%
TECHNOLOGY · Cap: $180.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 902266% more annual revenue ($56.67B vs $6.28M). NVS leads profitability with a 24.7% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VUZI
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-243.2%
Fair Value
$48.69
Current Price
$148.18
$99.49 premium
Intrinsic value data unavailable for VUZI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Revenue surging 76.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -89.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : VUZI
The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : VUZI
The primary concerns for VUZI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while VUZI is a hypergrowth play — different risk/reward profiles.
VUZI carries more volatility with a beta of 1.31 — expect wider price swings.
VUZI is growing revenue faster at 76.3% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 26/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Vuzix Corp Cmn Stk
TECHNOLOGY · CONSUMER ELECTRONICS · USA
Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?